Can denosumab be given every 3 months?
With studies showing non inferiority to zoledronic acid q 3 months in support of bone metastatic disease, would you consider extrapolating this data and giving denosumab every 3 months as well?
Community PollStarted
With studies showing non inferiority to zometa q 3 months in support of bone metastic disease, would you consider extrapolating this data and giving xgeva every 3 months as well?
26 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida
Answered on · Updated on
Not without data. The long half life and persistence of bisphosphonates in the bone is different from the shorter half life of monoclonal antibodies targeting RANK ligand (32 days). So dosing denosumab 120mg every 3 months would probably lead to suboptimal drug levels and increased bone turnover. Wh...
Join for free or sign in to see the full answer